Vimarsana
Biggest News Aggregation in the World

Analyzing Samples News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Analyzing Samples. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Analyzing Samples Today - Breaking & Trending Today

Zynerba stock rises as CBD gel improves rare disorder symptoms; autism program deferred - Vimarsana News

Zynerba stock rises as CBD gel improves rare disorder symptoms; autism program deferred

Zynerba Pharmaceuticals (ZYNE) stock rose ~8% premarket June 22 after the company said its transdermal CBD gel Zygel help improve behavior symptoms of 22q11.2 Deletion Syndrome in...

Novocure/Zai Lab's TTFields therapy meets main goal in phase 2 gastric cancer trial - Vimarsana News

Novocure/Zai Lab's TTFields therapy meets main goal in phase 2 gastric cancer trial

Novocure (NVCR) and Zai Lab (ZLAB) said a mid-stage study of their investigational device for Tumor Treating Fields (TTFields) met its main goal in patients with gastric...

Merck KGaA to invest ~€440M to boost manufacturing capacity in Ireland - Vimarsana News

Merck KGaA to invest ~€440M to boost manufacturing capacity in Ireland

Merck KGaA's (MKGAF) (MKKGY) will spend ~€440M to expand its membrane and filtration manufacturing capabilities in Ireland.The German company said the investment, which is the largest in...

Concert's CTP-543 helps hair regrowth in alopecia areata patients, meets trial's main goal - Vimarsana News

Concert's CTP-543 helps hair regrowth in alopecia areata patients, meets trial's main goal

Concert Pharmaceuticals (CNCE) said a phase 3 trial of its oral drug CTP-543 met the main goal of scalp hair regrowth at both doses in patients with with moderate to severe...

Tricida stops kidney disease study of veverimer due to administrative reasons - Vimarsana News

Tricida stops kidney disease study of veverimer due to administrative reasons

Tricida (TCDA) said it is stopping its VALOR-CKD trial of veverimer for kidney disease early due to administrative reasons pursuant to a study protocol to allow for six months of...